<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872378</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-AGREE Study</org_study_id>
    <nct_id>NCT00872378</nct_id>
  </id_info>
  <brief_title>The Effects of Exenatide After Gastric Restriction</brief_title>
  <acronym>AGREE</acronym>
  <official_title>A Pilot Study of the Effects of BYETTA® (Exenatide) on Weight Loss in Morbidly Obese Non Diabetic Patients Following Adjustable Gastric Banding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Specialty Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Specialty Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe change in body weight in non-diabetic morbidly obese
      patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide or
      placebo injections.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide plus lifestyle modification plan or placebo plus lifestyle modification plan.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in: 2 hour Oral Glucose Tolerance Test; Lipid panel; Comprehensive metabolic panel; Glycosylated hemoglobin A1c</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid intima media thickness(CIMT)</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>BYETTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years,

          2. Have a body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities (1991 NIH
             Guidelines for Bariatric Surgery),

          3. For women of childbearing age, must have a negative pregnancy test at screening, and
             agree to use barrier contraceptives for the duration of the study, AND

          4. Are able to understand and comply with the study process, and give informed consent.

        Exclusion Criteria:

          1. A diagnosis of type 1 diabetes mellitus,

          2. A diagnosis of type 2 diabetes mellitus (A diagnosis of T2DM will be a previous
             fasting plasma glucose greater than or equal to 126 mg/dL, or a random plasma glucose
             greater than 200 mg/dL),

          3. Have experienced hypersensitivity reaction or a worsening of glycemic control on
             Byetta® (exenatide),

          4. Patients with end stage renal disease or severe renal impairment,

          5. Patients with severe gastrointestinal disease, including gastroparesis,

          6. Liver function tests 2.5 standard deviations above normal values,

          7. Contraindication for bariatric surgery,

          8. Treatment with exenatide (Byetta) in the last three months,

          9. Currently using or have used within three months before this trial: sibutramine,
             orlistat, or phentermine(patients must also agree to not use these medications for the
             duration of the study),

         10. Treatment with any investigational drug in the last 30 days,

         11. Active malignancy, liver of kidney failure, symptomatic coronary heart disease, or
             severe psychiatric disease,

         12. History of malignancy other than basal cell skin carcinoma, OR

         13. In the opinion of the investigator, patient is abusing alcohol and/or drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J McCarthy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Services NorthWest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan E Boone, BS</last_name>
    <phone>541-322-1772</phone>
    <email>megan@advancedspecialtycare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Specialty Care</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan E Boone, BS</last_name>
      <phone>541-322-1772</phone>
      <email>megan@advancedspecialtycare.com</email>
    </contact>
    <investigator>
      <last_name>Ngocthuy Hughes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen B Archer, MD FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinology Services NorthWest</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan E Boone, BS</last_name>
      <phone>541-322-1772</phone>
      <email>megan@advancedspecialtycare.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Travis L Monchamp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>March 30, 2009</last_update_submitted>
  <last_update_submitted_qc>March 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Patrick J. McCarthy M.D., Endocrinologist</name_title>
    <organization>Endocrinology Services NorthWest</organization>
  </responsible_party>
  <keyword>Morbid Obesity</keyword>
  <keyword>LAP Band</keyword>
  <keyword>Adjustable Gastric Band</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Byetta</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>Bariatric Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

